Functional Neuromodulation Ltd.

At the North American Neuromodulation Society (NANS) meeting, Boston Scientific Corp. highlighted encouraging three-month results from a randomized trial of its Spectra Wavewriter spinal cord stimul

Clinical trials of devices designed to slow the progression of neurological conditions such as Alzheimer’s disease shouldn’t conflate symptom improvement with biomarker changes, FDA underscores in a M

The US neurostimulation technology market will grow nearly 46% over the next five years, driven by the introduction of more effective implantable neurostimulation devices and increasing awareness and

Edwards Lifesciences Corp. 's payments to clinical investigators who ran its PARTNER II trial totaled $32.5 million in 2014, in what appears to be the largest spending total of any device trial last